At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 364 enrolled
Drug / intervention
No Treatment Added +1 moredrug
Likely dose
Milnacipran Added 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia
In Brief
A Phase 3 clinical trial evaluating No Treatment Added and Milnacipran Added for Fibromyalgia. Completed, enrolled 364 participants across 60 sites.
Detailed Summary
To evaluate the safety, tolerability, and efficacy of milnacipran when taken with another drug called pregabalin in people with fibromyalgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionNov 2009
Study CompletionJan 2010
TodayJul 2026
First PostedNov 25, 2008
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.6 years ago
Interventions
No Treatment Addeddrug
No added treatment
Milnacipran Addeddrug
Milnacipran 100 mg/d added